Since both IGF-I and IGF-II are reported to be important activators of IGF-IR signaling in lung cancer [61–64], there is a good rationale for targeting the IR as well as the IGF-IR in order to achieve complete inhibition of the IGF axis. The gene discussed is IGF1R; the disease is lung carcinoma.